Xeljanz Side Effects Include Heart Attacks, Strokes, and Cancers
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Our law firm is investigating Xeljanz lawsuits filed against Pfizer, the pharmaceutical company responsible for Xeljanz — and, we contend, serious Xeljanz side effects. Related to this, there is a possible Xeljanz recall following the latest FDA regulatory action.
To start, it is unusual the FDA pointed out, again, in 2021 that there are cases of Xeljanz causing heart problems and Xeljanz causing cancer. We say that because those serious Xeljanz side effects were already “highlighted” by means of the Black Box Warning which was added to the Xeljanz drug label back in 2019. As such, it is possible the FDA may mandate a Xeljanz recall in the future, but this remains to be seen. Regardless, it is likely there will be Xeljanz lawsuits filed on behalf of patients who have suffered Xeljanz side effects such as heart attacks, strokes, and cancers.
This February 4, 2021, FDA Drug Safety Communication, “Initial safety trial results find increased risk of serious heart-related problems and cancer with arthritis and ulcerative colitis medicine Xeljanz, Xeljanz XR (tofacitinib)“, provides the latest details about these two Xeljanz safety issues: (1) Xeljanz causing heart problems; and (2) Xeljanz causing cancer.
As background, in 2012, Pfizer’s Xeljanz was approved by the FDA to treat adults with rheumatoid arthritis, and in 2017 the drug was approved by the FDA to treat psoriatic arthritis. Shortly thereafter, in 2018, the drug was approved by the FDA to treat ulcerative colitis. It is also indicated for the treatment of adult patients with moderately to severely active rheumatoid or active psoriatic arthritis who have had an inadequate response to certain other drugs.
Again, we remark about this noteworthy February 2021 FDA Xeljanz Drug Safety Communication being issued on top of the prior Xeljanz Black Box Warning. We think it will result in new Xeljanz lawsuits being filed for patients against Pfizer, as well as the prospect of a Xeljanz recall mandated by the FDA.
Some of the adverse drug events and side effects related to Xeljanz are:
- Heart Attacks
- Myocardial Infarction (MI)
- Strokes — Ischemic / due to a blood clot
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Arterial Thrombosis
Our law firm is investigating possible Xeljanz lawsuits for patients, whether or not there is a Xeljanz recall, and we would like to help you or someone you know with such a case.
We encourage you to submit a Xeljanz Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call our toll-free number, (800) 426-9535, to speak directly to attorney Tom Lamb about a possible drug injury case. Either way, you will get Mr. Lamb’s impressions — not an intake person, a paralegal, nor some other lawyer — about your case based on his many years of experience.
Most Recent Article About Xeljanz
Based on these several recent developments, we expect that there will be an FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq in the months to come. The focus of such will likely be these adverse drug events and side effects related to the JAK inhibitors class of drugs:
Myocardial Infarction (MI)
Strokes — Ischemic / due to a blood clot
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
To read more of this article, click below:
Last week we saw this April 8, 2021, Endpoints News article with a telling headline, “Series of JAK inhibitor delays may signal an upcoming FDA adcomm”, by Zachary Brennan, from which we get the following insights:
Three-month review delays from the FDA have become the norm in recent days for JAK inhibitors, some of which are seeking label expansions.
But the pushback of these action dates for AbbVie’s Rinvoq, Pfizer’s Xeljanz and abrocitinib, and Eli Lilly’s Olumiant may be a sign that the FDA is preparing to hold an advisory committee of outside experts to review the risk/benefit profiles of JAK inhibitors for atopic dermatitis, according to Leerink analyst Geoffrey Porges. This wouldn’t be the first time this year that the FDA wants to review a series of drugs before an adcomm as the agency is holding such a review later this month for cancer drugs that have previously won accelerated approvals.
We will continue to watch for new information about an increased risk of serious heart-related problems and cancer associated with Xeljanz. And we will look for any related developments concerning the JAK inhibitors class of drugs, such as the possible FDA Advisory Committee Meeting for Xeljanz, Olumiant, and Rinvoq mentioned above.
At the present time, our law firm is investigating possible Xeljanz drug injury lawsuits for people who have been diagnosed with heart-related problems or cancer.[Read article in full at original source]
Earlier articles about Xeljanz by attorney Tom Lamb on the Side Effects Blog:
- Are Heart Problems and Cancers JAK Inhibitors Drug Class Safety Issues?
- New Xeljanz Warnings From FDA in 2021; Are Other JAK Inhibitors Next?
- Xeljanz 2021 FDA Warnings: Xeljanz Causing Heart Problems and Xeljanz Causing Cancer
- Xeljanz Side Effects Include Blood Clots, Pulmonary Embolism, And Serious Infections
- Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
- Xeljanz FDA Drug Safety Communication About Increased Risks of Blood Clots And Death
- Serious Side Effects For Xeljanz 10 mg Dose Leads To European Drug Safety Regulatory Action
- Xeljanz Used For Ulcerative Colitis May Increase Risk Of Pulmonary Embolism
More articles about Xeljanz on our Drug Safety Developments website:
- Health Canada Issues Safety Review for Xeljanz in April 2021
- Xeljanz Safety Trial Results Which May Lead to Xeljanz Recall
- Will There Be a Xeljanz Recall in the Future?